Home LiteratureArticle Details
PMID: 8411068 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients.

Journal of medical genetics ·Vol. 30 ·No. 9 ·1993-09-00 ·Pages 737-44

Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E

Abstract

This report is the second part of a trilogy from a multidisciplinary study which was undertaken to record the relationships between clinical severity and dystrophin gene and protein expression. The aim in part 2 was to correlate the effect of gene deletions on protein expression in individual patients with well defined clinical phenotypes. Among the DMD patients, most of the deletions/duplications disrupted the open reading frame, but three patients had in frame deletions. Some of the intermediate D/BMD patients had mutations which were frameshifting while others were in frame. All of the deletions/duplications in the BMD patients maintained the open reading frame and 25/26 deletions in typical BMD group 5 started with exon 45. The deletion of single exon 44 was the most common mutation in patients from groups 1 to 3. Dystrophin was detected in sections and blots from 58% of the DMD patients with a size that was compatible with synthesis from mRNA in which the reading frame had been restored. Certain deletions were particularly associated with the occurrence of limited dystrophin synthesis in DMD patients. For example, 9/11 DMD patients missing single exons had some detectable dystrophin labelling compared with 10/24 who had deletions affecting more than one exon. All patients missing single exon 44 or 45 had some dystrophin. Deletions starting or finishing with exons 3 or 51 (8/9) cases were usually associated with dystrophin synthesis whereas those starting or finishing with exons 46 or 52 (11/11) were not. Formal IQ assessments (verbal, performance, and full scores) were available for 47 patients. Mean IQ score among the DMD patients was 83 and no clear relationship was found between gene mutations and IQ. The mutations in patients with a particularly severe deficit of verbal IQ were spread throughout the gene.

MeSH Terms
Adolescent Adult Aged Blotting, Western Child Child, Preschool Cohort Studies Dystrophin/biosynthesis,chemistry,genetics Female Frameshift Mutation Gene Deletion Genetic Linkage Genotype Humans Intellectual Disability/genetics Intelligence Tests Male Middle Aged Multigene Family Muscular Dystrophies/genetics,metabolism,pathology Phenotype Severity of Illness Index X Chromosome
Chemicals
Dystrophin
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Nicholson L V
Muscular Dystrophy Group Research Laboratories, Newcastle General Hospital, Newcastle upon Tyne, UK.
Johnson M A
Bushby K M
Gardner-Medwin D
Curtis A
Ginjaar I B
den Dunnen J T
Welch J L
Butler T J
Bakker E
References (53)
53 references, click to expand
  1. Mapping of dystrophin brain promoter: a deletion of this region is compatible with normal intellect.
    Neuromuscul Disord. 1991;1(5):327-31 PMID: 1822342
  2. A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues.
    Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5346-50 PMID: 1319059
  3. Dystrophin in frameshift deletion patients with Becker muscular dystrophy.
    Am J Hum Genet. 1992 Sep;51(3):562-70 PMID: 1496988
  4. A deletion including the brain promoter of the Duchenne muscular dystrophy gene is not associated with mental retardation.
    Neuromuscul Disord. 1992;2(2):117-20 PMID: 1422198
  5. Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame.
    J Med Genet. 1992 Dec;29(12):892-6 PMID: 1479604
  6. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability.
    Neuromuscul Disord. 1992;2(4):269-76 PMID: 1483053
  7. Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions.
    Am J Med Genet. 1992 Oct 1;44(3):378-81 PMID: 1488990
  8. Additional dystrophin fragment in Becker muscular dystrophy patients: correlation with the pattern of DNA deletion.
    Am J Med Genet. 1992 Oct 1;44(3):382-4 PMID: 1488991
  9. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.
    J Neurol. 1993 Feb;240(2):105-12 PMID: 8437017
  10. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history.
    J Neurol. 1993 Feb;240(2):98-104 PMID: 8437027
  11. Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice.
    Hum Mol Genet. 1992 Apr;1(1):35-40 PMID: 1301134
  12. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy.
    Arch Dis Child. 1993 May;68(5):632-6 PMID: 8323331
  13. Differences between verbal and performance IQs on the Wechsler Intelligence Scale for Children.
    J Consult Psychol. 1951 Feb;15(1):62-7 PMID: 14814256
  14. The standardization of the Wechsler intelligence scale for children.
    J Consult Psychol. 1950 Apr;14(2):99-110 PMID: 15412213
  15. Becker muscular dystrophy: correlation of deletion type with clinical severity.
    J Med Genet. 1990 Apr;27(4):236-9 PMID: 2325103
  16. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.
    Acta Neuropathol. 1990;80(3):239-50 PMID: 2205076
  17. Somatic reversion/suppression of the mouse mdx phenotype in vivo.
    J Neurol Sci. 1990 Oct;99(1):9-25 PMID: 2250176
  18. Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies.
    Cell. 1990 Dec 21;63(6):1239-48 PMID: 2261642
  19. Specificity of expression of the muscle and brain dystrophin gene promoters in muscle and brain cells.
    Neuron. 1990 Dec;5(6):881-8 PMID: 2268434
  20. Analysis of verbal disability in Duchenne muscular dystrophy.
    J Nerv Ment Dis. 1980 Jul;168(7):419-23 PMID: 7400791
  21. Intellect and behaviour in Duchenne muscular dystrophy.
    Dev Med Child Neurol. 1981 Oct;23(5):577-90 PMID: 7286451
  22. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.
    Muscle Nerve. 1983 Feb;6(2):91-103 PMID: 6343858
  23. The diagnosis of muscular dystrophy in patients referred for language delay.
    J Child Psychol Psychiatry. 1986 Jul;27(4):545-9 PMID: 3745353
  24. Dystrophin: the protein product of the Duchenne muscular dystrophy locus.
    Cell. 1987 Dec 24;51(6):919-28 PMID: 3319190
  25. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein.
    Cell. 1988 Apr 22;53(2):219-28 PMID: 3282674
  26. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.
    N Engl J Med. 1988 May 26;318(21):1363-8 PMID: 3285207
  27. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.
    Genomics. 1988 Jan;2(1):90-5 PMID: 3384440
  28. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy.
    Science. 1988 Nov 4;242(4879):755-9 PMID: 3055295
  29. Duchenne muscular dystrophy gene product is not identical in muscle and brain.
    Nature. 1989 Jan 5;337(6202):76-8 PMID: 2909892
  30. Genetic abnormalities in Duchenne and Becker dystrophies: clinical correlations.
    Neurology. 1989 Apr;39(4):461-5 PMID: 2648185
  31. Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies.
    Neurology. 1989 Apr;39(4):465-74 PMID: 2927671
  32. Improved diagnosis of Becker muscular dystrophy by dystrophin testing.
    Neurology. 1989 Aug;39(8):1011-7 PMID: 2668783
  33. High resolution deletion breakpoint mapping in the DMD gene by whole cosmid hybridization.
    Nucleic Acids Res. 1989 Jul 25;17(14):5611-21 PMID: 2569720
  34. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy.
    J Med Genet. 1989 Nov;26(11):682-93 PMID: 2585468
  35. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications.
    Am J Hum Genet. 1989 Dec;45(6):835-47 PMID: 2573997
  36. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin.
    Nature. 1990 Jan 11;343(6254):180-2 PMID: 2404210
  37. Dystrophin gene transcribed from different promoters in neuronal and glial cells.
    Nature. 1990 Mar 1;344(6261):64-5 PMID: 2406613
  38. Dystrophin abnormalities in Duchenne/Becker muscular dystrophy.
    Neuron. 1989 Jan;2(1):1019-29 PMID: 2696500
  39. Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin.
    Am J Hum Genet. 1991 Feb;48(2):295-304 PMID: 1990838
  40. Dystrophin is transcribed in brain from a distant upstream promoter.
    Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1276-80 PMID: 1996328
  41. Is dystrophin labelling always discontinuous in Becker muscular dystrophy?
    J Neurol Sci. 1991 Feb;101(2):187-92 PMID: 2033404
  42. Sequences of junction fragments in the deletion-prone region of the dystrophin gene.
    Genomics. 1991 May;10(1):57-67 PMID: 2045110
  43. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies.
    Am J Hum Genet. 1991 Jul;49(1):54-67 PMID: 2063877
  44. Direct detection of dystrophin gene rearrangements by analysis of dystrophin mRNA in peripheral blood lymphocytes.
    Am J Hum Genet. 1991 Aug;49(2):298-310 PMID: 1867192
  45. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.
    Am J Hum Genet. 1989 Oct;45(4):498-506 PMID: 2491009
  46. Apparent association of mental retardation and specific patterns of deletions screened with probes cf56a and cf23a in Duchenne muscular dystrophy.
    Am J Med Genet. 1991 Jun 15;39(4):437-41 PMID: 1877622
  47. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs.
    Nature. 1991 Aug 29;352(6338):815-8 PMID: 1881437
  48. Dystrophin as a diagnostic marker in Duchenne and Becker muscular dystrophy. Correlation of immunofluorescence and western blot.
    Neuropediatrics. 1991 Aug;22(3):152-62 PMID: 1944822
  49. Human dystrophin gene transfer: production and expression of a functional recombinant DNA-based gene.
    Hum Genet. 1991 Nov;88(1):53-8 PMID: 1959926
  50. Head circumference and intellectual performance of patients with Duchenne muscular dystrophy.
    Dev Med Child Neurol. 1991 Oct;33(10):884-90 PMID: 1743411
  51. Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy.
    J Med Genet. 1991 Dec;28(12):860-4 PMID: 1757963
  52. Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro.
    FEBS Lett. 1992 Jan 20;296(2):128-34 PMID: 1733767
  53. A transposon-like element in the deletion-prone region of the dystrophin gene.
    Genomics. 1992 Jul;13(3):594-600 PMID: 1322353
Article Info
Journal
Journal of medical genetics
Abbr.
J Med Genet
ISSN
0022-2593
Published
1993-09-00
Pages
737-44
Language
English
Region
England
NLM ID
2985087R
PMCID
PMC1016530
Subset
IM
Grants
Wellcome Trust · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]